Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8453626rdf:typepubmed:Citationlld:pubmed
pubmed-article:8453626lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C1512658lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C0678222lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C0006141lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C0684321lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C0443199lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:8453626lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:8453626pubmed:issue7lld:pubmed
pubmed-article:8453626pubmed:dateCreated1993-4-21lld:pubmed
pubmed-article:8453626pubmed:abstractTextWe have shown recently that the plant alkaloid camptothecin and its derivatives inhibited growth of human carcinoma and melanoma cells in vitro and induced regression of advanced human malignant melanoma tumors growing in immunodeficient (nude) mice. Here, we have extended these studies to show that the camptothecin derivative 9-nitro-20(S)- camptothecin (9NC) induces complete regression of advanced breast carcinoma tumors growing in nude mice. We also report that 9NC inhibits growth of nontumorigenic and tumorigenic breast cells in vitro. However, flow cytometry studies show that 9NC elicits differential effects on the cell cycle of nontumorigenic and tumorigenic cells. In general, 9NC-treated nontumorigenic cells accumulate slowly at the G2 phase of the cell cycle with no cell death. In contrast, 9NC-treated tumorigenic cells transverse rapidly from G1 to S phase followed by cell death. Removal of 9NC from the cell cultures resulted in most nontumorigenic cells dividing, whereas tumorigenic cells continued to die after removal of 9NC. Taken together, the findings indicate a different response of nontumorigenic and tumorigenic breast cells to 9NC.lld:pubmed
pubmed-article:8453626pubmed:languageenglld:pubmed
pubmed-article:8453626pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453626pubmed:citationSubsetIMlld:pubmed
pubmed-article:8453626pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453626pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453626pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453626pubmed:statusMEDLINElld:pubmed
pubmed-article:8453626pubmed:monthAprlld:pubmed
pubmed-article:8453626pubmed:issn0008-5472lld:pubmed
pubmed-article:8453626pubmed:authorpubmed-author:GiovanellaB...lld:pubmed
pubmed-article:8453626pubmed:authorpubmed-author:EarlyJ AJAlld:pubmed
pubmed-article:8453626pubmed:authorpubmed-author:PantazisPPlld:pubmed
pubmed-article:8453626pubmed:authorpubmed-author:MendozaJ TJTlld:pubmed
pubmed-article:8453626pubmed:authorpubmed-author:HinzH RHRlld:pubmed
pubmed-article:8453626pubmed:authorpubmed-author:KozielskiA...lld:pubmed
pubmed-article:8453626pubmed:issnTypePrintlld:pubmed
pubmed-article:8453626pubmed:day1lld:pubmed
pubmed-article:8453626pubmed:volume53lld:pubmed
pubmed-article:8453626pubmed:ownerNLMlld:pubmed
pubmed-article:8453626pubmed:authorsCompleteYlld:pubmed
pubmed-article:8453626pubmed:pagination1577-82lld:pubmed
pubmed-article:8453626pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:meshHeadingpubmed-meshheading:8453626-...lld:pubmed
pubmed-article:8453626pubmed:year1993lld:pubmed
pubmed-article:8453626pubmed:articleTitleRegression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro.lld:pubmed
pubmed-article:8453626pubmed:affiliationStehlin Foundation for Cancer Research, Houston, Texas 77003.lld:pubmed
pubmed-article:8453626pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8453626pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:8453626pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8453626lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8453626lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8453626lld:pubmed